AUF1 Gene Therapy Limited Muscle Loss After Injury in Mice
Mice kept near normal strength after a severe muscle injury when given extra AUF1, by virus or by mRNA. Two authors cofounded the company developing it, and no human has received it.
Pillar
Biotech
Drug pipelines, platforms and company data, read against the primary source.
18 articles
An Oral Pill for Angioedema Attacks: Relief in 1.3 Hours
A crossover trial in a rare disease, funded by the drugmaker: each patient treated one attack with the pill and one with placebo. The result is large and the analysis smaller than the enrollment.
A Parkinson's Pill That Skips Dopamine Cut Off Time by 37 Minutes
A new mechanism, a positive primary endpoint and a modest effect size. Everything here comes from a company release and a congress talk, not a peer reviewed paper.
Reading Iambic's S-1: An AI Drug IPO, Risk Factors First
One drug in early clinical testing, a $245 million accumulated deficit, and a platform the company itself calls unproven. The prospectus is more candid than the headlines.
Seven FDA Decisions Due by Christmas, and the Trials Behind Them
Every date below comes from the company itself. CagriSema has no published goal date, only a quarter. One file arrives after an advisory committee voted 9 to 3 against.
Anthropic Moves Into Biology: What Is Announced vs Shown
Four launches in three months. One produced a preprint about an enzyme system whose function is still unknown. The rest are access rules, pilots and promises.
Semaglutide's Heart Benefit Is Not Just About Weight Loss
Known risk factors explain at most about half of the 20% drop in heart events, and the frailest patients still benefit. Widening eligibility to a BMI of 25 is a different question.
Orforglipron Worked Across Menopause Stages, With One Asterisk
Women lost 12.8% to 14.4% of their weight on the top dose without diabetes. The diabetes trial tells a shakier story, built partly on a subgroup of 10 women.
One Insulin Shot a Week: What the Efsitora Approval Covers
Efsitora matched daily insulin on HbA1c in four trials and trades 365 injections for 52. In type 1 diabetes, severe lows were three times as common, which is why the label stops at type 2.
Lp(a): The Heart Risk Factor Science Still Can't Treat
Pelacarsen lowered Lp(a) in 8,323 HORIZON patients, but heart attacks and strokes did not fall. Why that gap between biomarker and outcome matters.
The First PCSK9 Pill Is Here. The Proof Still Comes From a Shot
A daily tablet now cuts LDL by more than half, while the injectable version of the same drug class was linked to 20% fewer deaths in people with no prior heart attack.
Retatrutide Takes Weight Off. Viking Bets a Monthly Shot Keeps It
Retatrutide's 20.8% assumes nobody quit, and Viking's 90% comes from a group of 11. The numbers behind the two biggest obesity drug headlines of September.
Aprocitentan: Another Dial for Hard to Control Blood Pressure
Against placebo, the endothelin blocker lowered systolic pressure by about 4 mmHg on top of three drugs. New post hoc data on obesity and kidney risk.
CagriSema and EloraTZP Both Beat Tirzepatide. Read the Doses
Novo won at the low end of the dose range, 12.4 versus 9.1 percent. Lilly won at the top, 23.3 versus 14.8, and lost up to one patient in four to side effects.
Myostatin Blockers Cut GLP-1 Muscle Loss. Strength Is Unproven
Trevogrumab and apitegromab saved kilograms of lean tissue in phase 2 trials, but no study has yet shown that it makes anyone stronger.
A GLP-1 Pill Against Insulin: What ACHIEVE-4 Proved for the Heart
Orforglipron cleared a heart safety bar against insulin glargine, 4.2 versus 5.0 percent, and posted a mortality gap the trial was never built to prove.
The Pill Duel: Orforglipron Beats Oral Semaglutide Head to Head
ACHIEVE-3, 1,698 adults, 52 weeks: in the primary analysis HbA1c fell 1.91 points against 1.47. A real head to head, run by one of the duelists.
The Race to Keep Muscle on GLP-1s Reaches Phase 2
Sironax's FORGE-LM trial is half enrolled. The endpoint is body composition, which is the right question. Enrollment, though, is not a result.
Get Facts First, every Sunday
One email a week: the 5 facts that mattered in AI, health and longevity, each checked against the original source. No spam. Unsubscribe in one click.
By subscribing you agree to receive the newsletter. See the privacy policy.